Coherus biosciences, inc. (CHRS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net income (loss)

145,437

89,833

-11,990

-117,859

-185,111

-209,409

-195,882

-196,049

-207,766

-238,286

-265,161

-122,324

-137,072

-127,788

-104,424

-259,753

-248,637

-223,938

-200,381

-136,810

-102,846

-87,177

0

0

0

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization

3,216

3,300

2,782

2,741

2,969

3,200

3,550

3,522

3,457

3,400

3,269

3,252

3,144

2,996

2,800

2,683

2,354

1,869

1,503

1,059

790

674

0

0

0

Remeasurement of fair-value contingent consideration

-

-

-

-

-

-3,230

-2,690

-2,325

-2,442

-2,260

-2,230

-4,150

4,505

4,305

3,930

5,645

575

4,599

0

0

0

-

-

-

-

Provision for other receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,300

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

33,652

33,591

35,146

34,873

35,571

34,797

34,302

33,925

34,307

33,397

32,750

32,837

29,913

27,421

24,910

21,384

19,857

16,721

15,373

13,364

9,953

11,062

0

0

0

Non-cash accretion of discount on marketable securities

-

-

-

-

-

301

275

150

181

156

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Remeasurement of convertible preferred stock warrant and embedded derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,899

0

0

0

Preferred stock issued in exchange for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

147

0

0

0

Non-cash interest expense from amortization of debt discount

2,419

2,339

2,110

1,886

1,673

1,484

1,450

1,417

1,384

1,352

1,320

1,290

1,260

1,041

723

412

91

-38

0

0

0

-

-

0

0

Excess and obsolete inventory

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-cash adjustments

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Excess and obsolete inventory

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash operating lease expense

1,894

1,789

1,305

818

405

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Trade receivables, net

121,142

141,992

89,646

77,385

46,476

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables from collaboration and license agreement

-

-

-

-

-

-

-

-

-

-1,859

-419

-419

-1,169

299

-121

-1,035

-820

-857

0

0

0

-

-

-

-

Inventory

51,360

48,184

36,635

22,190

11,916

5,484

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables from related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Notes receivable from related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-107

0

0

0

Prepaid manufacturing

3,429

672

-4,395

-3,522

-5,957

-7,063

-6,984

-18,943

-9,474

-7,788

28,233

42,318

25,818

16,119

0

0

0

-

-

-

-

14,692

0

0

0

Other prepaid and current assets

1,115

2,126

-145

2,377

2,368

-1,146

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other prepaid assets

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-125

270

-1,897

-1,111

-2,581

-1,887

4,386

3,329

0

0

0

-

-

-

-

Other assets, non-current

-

-

-

-

-

-

-

-

-

-

-

-

-

-88

-88

-128

-897

-42

0

0

0

-

-

-

-

Accounts payable

8,898

9,893

6,020

6,056

-3,197

-301

-2,369

-2,317

2,387

-3,810

-12,521

-1,421

-5,433

-4,965

-2,338

3,955

8,580

18,404

22,177

9,146

2,754

3,629

0

0

0

Accounts payable - related parties

-

-

-

-

-

-233

-5

-388

-2,075

-644

-2,855

-2,042

-1,385

-2,671

-232

-3,079

-229

1,528

-1,871

2,489

1,435

1,637

0

0

0

Accrued rebates, fees and reserve

54,212

51,120

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued rebates, fees and returns

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation

6,301

10,035

6,800

6,975

4,615

8,466

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued and other liabilities

10,494

10,386

7,699

5,083

3,593

69

-2,420

-6,674

-10,745

-14,079

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

Lease liabilities

-1,993

-2,010

-1,590

-1,020

-506

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-1,562

-1,785

-87,865

-81,039

-93,236

-60,336

18,570

25,441

32,294

-6,420

7,193

4,949

19,848

0

0

0

Advance payments under license agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

-260

0

0

0

-

-

-

-

-

-

0

0

Contingent liability to collaborator

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20,150

0

0

0

Other liabilities, non-current

0

-30

-138

-241

-345

-428

-410

-254

28

242

446

519

287

128

204

433

471

516

314

-45

293

299

0

0

0

Net cash provided by (used in) operating activities

98,815

28,355

-36,718

-134,458

-182,665

-159,266

-141,825

-140,549

-160,593

-200,286

-257,256

-277,691

-249,506

-252,545

-160,086

-157,793

-151,244

-107,990

-146,842

-92,357

-71,734

-23,927

0

0

0

Net cash acquired from acquisition of InteKrin Therapeutics Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,334

0

0

0

Purchases of property and equipment

3,270

1,822

1,649

1,220

1,043

789

684

2,007

2,963

4,573

8,030

6,718

6,058

6,515

4,393

6,292

6,999

6,164

5,209

3,617

3,902

2,849

0

0

0

Proceeds from disposal of property and equipment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investments in marketable securities

5,371

20,235

20,235

14,864

44,633

42,869

42,869

57,351

37,557

74,344

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

851

-12,732

9,116

22,216

-3,206

-1,188

-2,583

13,312

33,980

-4,417

-22,374

-51,580

-55,945

-6,515

-4,393

-7,077

-7,784

-6,949

-6,004

-3,627

-3,912

-525

0

0

0

Financing activities
Proceeds from common stock offering, net of underwriters discounts, commissions and offering costs

0

8,153

9,615

9,404

108,248

101,748

31,725

106,936

8,092

131,305

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

75,000

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible notes - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

25,000

0

0

0

-

-

-

-

-

-

-

-

Proceeds from term loan, net of issuance costs

79

72,955

72,955

73,061

72,876

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuances of common stock upon exercise of stock options

9,913

5,558

5,488

2,968

2,305

2,082

1,816

646

442

482

1,799

3,293

3,279

3,312

2,371

1,246

1,559

1,429

1,051

583

213

55

0

0

0

Payments of common stock offering issuance costs

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments of convertible notes issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

739

0

0

0

-

-

-

-

-

-

-

-

Taxes paid related to net share settlement of bonus payout in RSUs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

11,816

89,370

90,763

88,138

185,020

105,421

109,720

183,744

83,668

206,787

255,894

182,066

251,333

226,179

170,510

179,719

223,261

122,689

206,125

193,878

135,219

135,956

0

0

0

Repurchase of restricted common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

0

0

0

Effect of exchange rate changes in cash, cash equivalents and restricted cash

-140

-276

-32

26

345

468

323

136

32

-120

-384

-359

-516

-398

-45

-21

189

84

-463

-675

-754

-666

0

0

0

Net increase in cash, cash equivalents and restricted cash

111,342

104,717

63,129

-24,078

-506

-54,565

-34,365

56,643

-42,913

1,964

-24,120

-147,564

-54,634

-33,279

5,986

14,828

64,422

7,834

52,816

97,219

58,819

110,838

0

0

0

Supplemental disclosure of cash flow information
Unpaid upfront license fee to Innovent included in Accounts Payable as of March 31, 2020

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash bonus payment settled in common stock

148

0

1,350

1,350

1,350

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of non-cash investing and financing activities
Right-of-use assets obtained in exchange for lease obligations related to operating leases

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for lease obligations related to finance leases

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-